Media Center
CreatiPhage & Wenzhou Capital | Jointly Building a New Platform, Partnering with CreatiPhage.
Date：2023-02-15
On September 30, 2022, at 10:00 AM, CreatiPhage (Shanghai) Biotechnology Co., Ltd. and Wenzhou Capital jointly signed a cooperation agreement for angel round equity investment.
Invited guests in attendance included representatives from Fudan University Shanghai Medical College, Minsheng Bank, Industrial Bank, Bank of China, Wenzhou Capital, Dongnian Medical Technology,
CITIC Taikang Fund, Ultraordinary Medical, Ruishan Capital, medical experts, and representatives from both, with approximately 20 people attending the signing ceremony.
Bacteriophages are viruses that infect bacteria, with a simple structure and an obligate intracellular parasitic lifestyle, nearly ubiquitous in every corner of the world. Through mechanisms such as lysis,
lysogeny, and horizontal gene transfer, bacteriophages can influence the life cycle and evolution of their hosts, playing a significant ecological role. Due to their characteristic of not infecting eukaryotic cells
and their bacteriophage specificity that results in minimal impact on normal flora, they possess sufficient safety. Bacteriophage therapy is not constrained by bacterial resistance and has a disruptive effect on
drug-resistant bacteria. As they prey on bacteria, they also self-replicate, making them perfect predators. The CreatiPhage team, through nearly a hundred cases of bacteriophage clinical practice over five
years, has effectively validated the safety and efficacy of bacteriophage therapy and is confident in its prospects.
This event witnesses the collaboration between China's most promising bacteriophage research and development team and Shanghai Wenzhou Investment, recognized as the Best Early-Stage Investment
Institution in China's medical and health sector for 2021-2022. This partnership will advantageously advance the "clinical translation of bacteriophages" and their in-depth application scenarios in animal health,
food safety, and other areas, benefiting more fields threatened by antimicrobial resistance.
Add: 3333 Huaning Road, Shanghai
Tel: 0086-400-668-7738
©Shanghai ICP reserve No. 2022031782-1 CreatiPhage Biotechnology Co., Ltd. All rights reserved. Designed by JCE
